seborrheicderma's Recent CancerCompass Activity

Load more activity
Loading more activity

About seborrheicderma

After five decades of almost exclusive cortisone therapy, there is a new active substance developed in Vienna against the diseases. Success in drug discovery in Austria: A few days ago in Washington seborrheic dermatitis scalp hair loss, scientists at the American Academy of Dermatology (AAD) congress reported on very good treatment results with the active substance ASM 981 (ascomycin 981 or pimecrolimus) developed in Vienna against atopic dermatitis and psoriasis. The substance appears to be the first important innovation in this field for five decades (cortisone).

"The results suggest that we have a new possible therapy as

Alternative to topical steroids (cortisone ointments) for the long-term treatment of atopic dermatitis. The way we treat such eczema is likely to change fundamentally in the future, "Dr. Adelaide Hebert from the University of Texas.

The results of a study with 700 children and adolescents suffering from atopic dermatitis (formerly neurodermatitis) were presented at the congress in Washington. Up to 20 per cent of the children seborrheic keratosis home treatment have symptoms of this chronic inflammatory condition, which is difficult to treat. To date, there has been virtually exclusively cortisone therapy. However, the substance can have significant side effects.

In the new scientific study was the effect of conventional

Treatment (cortisone) with that using ASM 981 in ointment form. It turned out that 61 percent of the patients who received the drug developed in Austria (by the Novartis Research Institute) had no major skin problems for six months. In the comparison group, it was only 35 percent.

The active substance of the new drug is a so-called macrolide, which was originally obtained from Streptomyces hygroscopicus. Biochemistry Kundl has put production on its feet. Ascomycin prevents the release of inflammatory agents such as interleukin-2, interleukin-4 and gamma interferon from the T cells and mast cells seborrheic dermatitis scalp hair loss. Just as important as the use in atopic dermatitis is probably in. Future the use of ASM 981 in tablet form in the treatment of moderate to severe psoriasis (psoriasis). Again, the new substance could significantly facilitate the lot of patients.

We care about your feedback. Let us know how we can improve your CancerCompass experience.